BR112021019241A8 - Flavivírus vivos e atenuados, ácidos nucleicos de rna e de cdna, células recombinantes, clones de cdna, composições imunogênicas e vírus do nilo ocidental (wnv) vivo e atenuado - Google Patents

Flavivírus vivos e atenuados, ácidos nucleicos de rna e de cdna, células recombinantes, clones de cdna, composições imunogênicas e vírus do nilo ocidental (wnv) vivo e atenuado

Info

Publication number
BR112021019241A8
BR112021019241A8 BR112021019241A BR112021019241A BR112021019241A8 BR 112021019241 A8 BR112021019241 A8 BR 112021019241A8 BR 112021019241 A BR112021019241 A BR 112021019241A BR 112021019241 A BR112021019241 A BR 112021019241A BR 112021019241 A8 BR112021019241 A8 BR 112021019241A8
Authority
BR
Brazil
Prior art keywords
live
atenuated
wnv
cdna
nucleic acids
Prior art date
Application number
BR112021019241A
Other languages
English (en)
Other versions
BR112021019241A2 (pt
Inventor
Pardigon Nathalie
Basset Justine
Augusto Rey Felix
Original Assignee
Pasteur Institut
Univ Paris
Centre Nat Rech Scient
Univ Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Univ Paris, Centre Nat Rech Scient, Univ Paris Cite filed Critical Pasteur Institut
Publication of BR112021019241A2 publication Critical patent/BR112021019241A2/pt
Publication of BR112021019241A8 publication Critical patent/BR112021019241A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

FLAVIVÍRUS VIVOS E ATENUADOS, ÁCIDOS NUCLEICOS DE RNA E DE CDNA, CÉLULAS RECOMBINANTES, CLONES DE CDNA, COMPOSIÇÕES IMUNOGÊNICAS E VÍRUS DO NILO OCIDENTAL (WNV) VIVO E ATENUADO. O presente pedido diz respeito à atenuação de um flavivírus, tal como um Vírus do Nilo Ocidental (WNV), Vírus Zika (ZIKV), Vírus da Encefalite Japonesa (JEV), Vírus da dengue (DV), particularmente o DV4, ou Vírus Usutu. O pedido fornece particularmente um flavivírus vivo e atenuado, como um WNV ou ZIKV vivo e atenuado, compreendendo uma proteína M mutada. A referida proteína M mutada compreende, ou consiste em, uma sequência na qual, pelo menos, os aminoácidos nas posições 36 e 43 da referida sequência estão mutados. O presente pedido também fornece exemplos de realização derivados do referido flavivírus vivo e atenuado, como um WNV ou ZIKV, tais como ácidos nucleicos, células, clones de cDNA, composições imunogênicas, bem como usos e métodos.
BR112021019241A 2019-03-28 2020-03-27 Flavivírus vivos e atenuados, ácidos nucleicos de rna e de cdna, células recombinantes, clones de cdna, composições imunogênicas e vírus do nilo ocidental (wnv) vivo e atenuado BR112021019241A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825734P 2019-03-28 2019-03-28
PCT/IB2020/000302 WO2020194063A1 (en) 2019-03-28 2020-03-27 A live and attenuated flavivirus comprising a mutated m protein

Publications (2)

Publication Number Publication Date
BR112021019241A2 BR112021019241A2 (pt) 2022-01-18
BR112021019241A8 true BR112021019241A8 (pt) 2022-12-06

Family

ID=70736788

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019241A BR112021019241A8 (pt) 2019-03-28 2020-03-27 Flavivírus vivos e atenuados, ácidos nucleicos de rna e de cdna, células recombinantes, clones de cdna, composições imunogênicas e vírus do nilo ocidental (wnv) vivo e atenuado

Country Status (6)

Country Link
US (1) US20230167415A1 (pt)
EP (1) EP3947655A1 (pt)
BR (1) BR112021019241A8 (pt)
CA (1) CA3129482A1 (pt)
IL (1) IL286658A (pt)
WO (1) WO2020194063A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022101463A1 (en) * 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
CA2584228C (en) * 2004-10-20 2015-05-05 Acambis Inc. Vaccines against japanese encephalitis virus and west nile virus
WO2016079560A1 (en) * 2014-11-21 2016-05-26 Institut Pasteur A live and attenuated japanese encephalitis virus comprising a mutated m protein

Also Published As

Publication number Publication date
US20230167415A1 (en) 2023-06-01
BR112021019241A2 (pt) 2022-01-18
WO2020194063A1 (en) 2020-10-01
IL286658A (en) 2021-12-01
CA3129482A1 (en) 2020-10-01
EP3947655A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
Romanova et al. Microevolution of tick-borne encephalitis virus in course of host alternation
RU2009121566A (ru) Стабилизация вакцин лиофилизацией
US9267114B2 (en) Flavivirus envelope protein mutations affecting virion disassembly
RU2007143529A (ru) Рекомбинантные флавивирусные вакцины
AR095598A1 (es) Composiciones y métodos para construcciones quiméricas del virus del dengue en vacunas
CA2584228A1 (en) Vaccines against japanese encephalitis virus and west nile virus
BR112021019241A8 (pt) Flavivírus vivos e atenuados, ácidos nucleicos de rna e de cdna, células recombinantes, clones de cdna, composições imunogênicas e vírus do nilo ocidental (wnv) vivo e atenuado
GEP20237575B (en) Stable vaccine compositions comprising inter alia live attenuated recombinant dengue virus and process for preparation thereof
JP2008520187A5 (pt)
DK0872553T3 (da) Kimæriske og/eller vækstbegrænsede flavivirus
Alkan et al. Ecuador Paraiso Escondido virus, a new flavivirus isolated from New World sand flies in Ecuador, is the first representative of a novel clade in the genus Flavivirus
BRPI0613362A8 (pt) polipeptídeo quimérico, polinucleotídeo, vetor viral, recombinante do sarampo, uso de um vetor viral, anticorpos, vetor, composição imunogênica e método de prevenção e/ou de tratamento de uma infecção
MY192806A (en) Compositions and methods of vaccination against dengue virus in children and young adults
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
JP2016513970A5 (pt)
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
JP2019520058A5 (pt)
PH12020550569A1 (en) A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
BR112021007105A2 (pt) Zika vírus recombinante vivo atenuado, zika vírus recombinante, partícula de zika vírus recombinante ou ácido nucleico de zika vírus recombinante, ácido nucleico recombinante, isolado ou substancialmente purificado, vetor, célula ou isolado, vacina, preparação farmacêutica, composição imunogênica, uso, e, métodos para tratar um sujeito com uma infecção viral por zika natural, reduzir a gravidade de uma infecção viral por zika natural em um sujeito ou prevenir um sujeito de contrair uma infecção viral por zika naturalmente, para gerar uma vacina de zika vírus vivo atenuado, zika vírus recombinante, partícula de zika vírus recombinante ou ácido nucleico de zika vírus recombinante e para preparar uma vacina compreendendo zika vírus recombinante vivo atenuado
BR112023001583A2 (pt) Polipeptídeos de ss-glucocerebrosidase (gcase) modificado, polinucleotídeo, partícula viral e composição
BR112023023249A2 (pt) Fator neurotrófico de codificação de vírion aav e usos do mesmo
WO2010135054A3 (en) Mutations in a toll-like receptor motif in the ns4b of classical swine fever virus skin brescia influences virulence in swine
BR112021020325A2 (pt) Vírus quimérico zika-encefalite japonesa
BR112022010680A2 (pt) Proteínas de ligação ao antígeno associado ao interferon e uso das mesmas
EA202092934A1 (ru) Композиции и способы для посттрансляционной модификации in vivo

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: INSTITUT PASTEUR (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; UNIVERSITE PARIS CITE (FR)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.